Mendus AB (publ)

IMMU · Nasdaq Stockholm · Healthcare

6.20SEK −2.4%last day

Price as of 2 October 2026

The price over the past year, with dividends: −7.5%

Performance

1 month

−15.8%

1 year

−7.5%

3 years, per year

−9.5%

5 years, per year

−39.4%

Largest fall, 3 years

−96.0%

Below the peak now

−99.2%

Volatility, 1 year

72.3%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

0.7

Dividend yield

0.0%

Return on equity

−18.8%

Net margin

–

Market value

39 m USD

Quality, value and trend

Where Mendus stands against every Nordic stock today. 100 is best.

Quality81

Profitability and a sound balance sheet over time. Better than 81% of Nordic stocks.

Value24

The price measured against earnings, assets and cash flow. Better than 24% of Nordic stocks.

Trend68

The price development over the past year. Better than 68% of Nordic stocks.

Combined61

Quality, value and trend together. Better than 61% of Nordic stocks.

About Mendus

Mendus AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 19 employees.

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis